Atherosclerosis Research

Atherosclerosis is a disease of the arterial system that is characterized by the accumulation of fatty deposits within arterial walls, known as 'atherosclerotic plaques'.

Atherosclerosis Research Products Targets

Products for Atherosclerosis Research - Page 17

Cat.No. Product Name Information/Activity
BCC1244 TGX-221 TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit, used for cancer treatment.
BCC3874 Wortmannin Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively.
BCC5861 740 Y-P 740 Y-P (PDGFR 740Y-P) is a potent and cell permeable PI3K activator.
BCC7522 PAF (C16) Endogenous platelet-activating factor (PAF)
BCN1682 Ginkgolide B Ginkgolide B (BN-52021), an important active terpenoid from Ginkgo biloba leaves, is reported to increase cell viability and decrease cell apoptosis.
BCC6699 PCA 4248 123875-01-4
BCC7335 WEB 2086 Apafant (WEB 2086), a potent platelet-activating factor (PAF) antagonist, inhibits PAF binding to human PAF receptors with a Ki of 9.9 nM.
BCC7068 BMY 45778 Non-prostanoid prostacyclin IP receptor partial agonist
BCC7315 (±)-Cloprostenol sodium salt Cloprostenol sodium salt (ICI 80996 sodium salt) is a potent synthetic prostaglandin analogue, acts as a luteolytic agent, and is a PGF2α receptor agonist.
BCC7843 16,16-Dimethyl Prostaglandin E2 16,16-Dimethyl prostaglandin E2 (16,16-dimethyl PGE2) is an orally active vertebrate Hematopoietic stem cells (HSCs) homeostasis critical regulator. 16,16-Dimethyl prostaglandin E2 can act through EP2/EP4 and has an interaction with the Wnt pathway.